Trial Profile

Phase III trial of remestemcel-L (MSC-100 mesenchymal stem cells) in adults with liver/gut graft-versus-host disease.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 23 Feb 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remestemcel-L (Primary)
Indications Graft-versus-host disease
Focus Registrational; Therapeutic Use
Sponsors Mesoblast

Most Recent Events

12 Feb 2015 According to a Mesoblast media release, JCR has filed for Japanese regulatory approval for JR-031 (Remestemcel-L) in acute graft-versus-host disease.
15 Sep 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com